| 邵 慧,陈愉生,李鸿茹.晚期肺腺癌EGFR-TKIs靶向治疗临床疗效的研究[J].肿瘤学杂志,2016,22(8):627-631. |
| 晚期肺腺癌EGFR-TKIs靶向治疗临床疗效的研究 |
| Clinical Research of EGFR-TKIs in the Treatment for Advanced Lung Adenocarcinoma |
| 投稿时间：2015-10-16 |
| DOI：10.11735/j.issn.1671-170X.2016.08.B004 |
|
 |
| 中文关键词: EGFR-TKIs 肺肿瘤 靶向治疗 |
| 英文关键词:EGFR-TKIs lung neoplasms targeted therapy |
| 基金项目: |
|
| 摘要点击次数: 1874 |
| 全文下载次数: 622 |
| 中文摘要: |
| 摘 要：［目的］ 探讨晚期肺腺癌患者表皮生长因子受体细胞内酪氨酸激酶抑制剂(EGFR-TKIs)靶向治疗的疗效和预后。［方法］ 经病理学或细胞学确诊的肺腺癌患者106例，口服靶向药物（吉非替尼或厄洛替尼）治疗，直至疾病进展，观察EGFR-TKIs对晚期肺腺癌的抗肿瘤疗效和预后。［结果］ 疾病控制率女性高于男性、不吸烟者高于吸烟者、脑转移者高于无脑转移者，差异均具有统计学意义(P=0.005，P=0.001，P=0.033)。女性无进展生存期高于男性(χ2=5.24，P=0.022)，不吸烟者无进展生存期高于吸烟者(χ2=10.98，P=0.001)，未发现有影响无进展生存期的独立影响因素。［结论］ 分子靶向药物对于晚期肺腺癌具有一定疗效，女性、不吸烟者、脑转移患者接受EGFR-TKIs治疗可获得较好的疾病控制率，女性、不吸烟患者无进展生存期较长。 |
| 英文摘要: |
| Abstract：［Objective］ To investigate the clinical efficacy and prognosis of EGFR-TKIs in the treatment for advanced lung adenocarcinoma.［Methods］ A total of 106 patients with advanced lung adenocarcinoma stage Ⅲ~Ⅳ who diagnosed by pathology or cytology were enrolled. All patients were given EGFR-TKIs(Gefitinib or Erlotinib) until disease progression.Anti-tumor efficacy of EGFR-TKIs for advanced lung adenocarcinoma was observed．［Results］ The disease control rate of EGFR-TKIs for female advanced lung adenocarcinoma patients were higher than that for male patients，non-smokers were higher than smokers，and patients with brain metastasis were higher than that without brain metastasis. All of them had statistically significant difference(P=0.005，P=0.001，P=0.033). The median progression free survival time of female patients was higher than that of male patients(χ2=5.24，P=0.022)，and non-smokers were higher than smokers(χ2=10.98，P=0.001). No independent prognostic factor was found which influenced the median progression free survival time. ［Conclusion］ Molecular targeted drug for advanced lung cancer is effective. Women，no smoking and brain metastasis can achieve a better disease control rate on EGFR-TKIs treatment. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |